The Liposome other research news

LIPO announced that it plans to develop ELL-12 as an adjunct to chemotherapy. The agent has anti-tumor action in mouse models of melanoma, lung cancer and leukemia, as well as in a model of prostate cancer. The agent is not myelosuppressive, and does not interact directly with DNA, as do conventional cancer therapies. ...